A Phase 4, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Tezepelumab in Patients With Severe Asthma, Including Underrepresented Racial and Clinical Groups: Initial Baseline Demographics and Clinical Characteristics From the PASSAGE Study

被引：0

作者：

Lugogo, N. L. ^{[1
]}

Sumino, K. ^{[2
]}

Akuthota, P. ^{[3
]}

Burnette, A. F. ^{[4
]}

Mathur, S. K. ^{[5
]}

Lindsley, A. W. ^{[6
]}

Llanos, J. ^{[7
]}

Marchese, C. ^{[8
]}

Cook, B. ^{[9
]}

Martin, N. ^{[10
]}

Ambrose, C. S. ^{[9
]}

Emmanuel, B. ^{[9
]}

机构：

[1] Univ Michigan, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA

[2] Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA

[3] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92093 USA

[4] Howard Univ, Div Allergy & Immunol, Washington, DC 20059 USA

[5] Univ Wisconsin, Dept Med, Div Allergy Pulm & Crit Care Med, Madison, WI USA

[6] Amgen Inc, US Med Affairs, Thousand Oaks, CA USA

[7] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA

[8] AstraZeneca, BioPharmaceut R&D, Resp & Immunol, Late Stage Dev, Gothenburg, Sweden

[9] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA

[10] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Cambridge, England

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A5374

引用

页数：3

共 50 条

[41] PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients
Remon, Jordi
Girard, Nicolas
Novello, Silvia
de Castro, Javier
Bigay-Game, Laurence
Bernabe, Reyes
Greillier, Laurent
Mosquera, Joaquin
Cousin, Sophie
Juan, Oscar
Sampayo, Miguel
Besse, Benjamin
CLINICAL LUNG CANCER, 2022, 23 (03) : E243 - E246
[42] Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.
Zimmer, Lisa
Eigentler, Thomas K.
Vaubel, Julia-Marianne
Mohr, Peter
Jradi, Zeinab
Kiecker, Felix
Utikal, Jochen
Berking, Carola
Kaempgen, Eckhart
Hauschild, Axel
Dippel, Edgar
Rompel, Rainer
Fluck, Michael
Stadler, Rudolf
Herbst, Rudolf
Terheyden, Patrick
Garbe, Claus
Loquai, Carmen
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[43] Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
Arima, Mitsuru
Inoue, Hirosuke
Nakao, Shintaro
Misumi, Akiko
Suzuki, Maya
Matsushita, Itsuka
Araki, Shunsuke
Yamashiro, Chiemi
Takahashi, Kazumasa
Ochiai, Masayuki
Yoshida, Noriko
Hirose, Masayuki
Kishimoto, Junji
Todaka, Koji
Hasegawa, Shunji
Kimura, Kazuhiro
Kusuhara, Koichi
Kondo, Hiroyuki
Ohga, Shouichi
Sonoda, Koh-Hei
BMJ OPEN, 2021, 11 (07):
[44] An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia
Patton, William Nigel
Lindeman, Robert
Butler, Andrew C.
Kipps, Thomas J.
Jewell, Roxanne C.
Laubscher, Kevin H.
Zhou, Yan Yan
Lewis, Eric
Sedoti, Donna
Witman, Philip
Fang, Lei
Chan, Geoffrey
LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2819 - 2825
[45] A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; Prelininary results.
Richardson, P
Jagannath, S
Hussein, M
Berenson, J
Singhal, S
Irwin, D
Williams, SF
Bensinger, W
Badros, AZ
Vescio, R
Kenvin, L
Yu, ZN
Olesnyckyj, M
Faleck, H
Zeldis, J
Knight, R
Anderson, KC
BLOOD, 2005, 106 (11) : 449A - 449A
[46] Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
Cuchel, Marina
Meagher, Emma A.
Theron, Hendrik du Toit
Blom, Dirk J.
Marais, A. David
Hegele, Robert A.
Averna, Maurizio R.
Sirtori, Cesare R.
Shah, Prediman K.
Gaudet, Daniel
Stefanutti, Claudia
Vigna, Giovanni B.
Du Plessis, Anna M. E.
Propert, Kathleen J.
Sasiela, William J.
Bloedon, LeAnne T.
Rader, Daniel J.
LANCET, 2013, 381 (9860) : 40 - 46
[47] A phase II, open-label, single-arm, efficacy, and safety study of MDV3100 in patients with hormone-naive prostate cancer
Baskin-Bey, E. S.
Holtkamp, G. M.
Smith, M. R.
Ouatas, T.
Phung, D.
Tombal, B.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[48] Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
Si, Lu
Zou, Zhengyun
Zhang, Weizhen
Fang, Meiyu
Zhang, Xiaoshi
Luo, Zhiguo
Chen, Jing
Huang, Gang
Zhang, Peng
Cheng, Ying
Liu, Jiwei
Liu, Jiyan
Zhang, Junping
Wu, Di
Chen, Yu
Ma, Xiaobiao
Wei, Xiaoting
Sun, Peng
Jia, Zhongwei
Guo, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1
Hu, Xiaojie
Wang, Jinhu
Li, Wenbin
Zeng, Kang
Li, Yanling
Tao, Juan
Guan, Zhonghai
Kang, Zhuang
Xu, Zhongyuan
Li, Changxing
Ma, Yaohui
Yang, Liu
Wu, Zhuli
Han, Pu
Lin, Hongmei
Li, Ben
Hui, Ai-Min
Wang, Xingli
Lin, Xiaoxi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
Yoko Edahiro
Kohshi Ohishi
Akihiko Gotoh
Katsuto Takenaka
Hirohiko Shibayama
Takayuki Shimizu
Kensuke Usuki
Kazuya Shimoda
Masafumi Ito
Scott A. VanWart
Oleh Zagrijtschuk
Albert Qin
Hiroaki Kawase
Narihisa Miyachi
Toshiaki Sato
Norio Komatsu
Keita Kirito
International Journal of Hematology, 2022, 116 : 215 - 227

← 1 2 3 4 5 →